Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Richard Dart

Medical Toxicology Aurora, CO Medical Doctor

NPI 1528082492 CMS profile 204780

12605 E 16Th Ave, Aurora, CO 80045

Open in the dashboard

General payments

$96,852

65 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,375,802 paid to institutions, not to them · program years 2020–2025

Through program year 2023, Richard Dart of Aurora, CO is reported in the CMS Open Payments database as having received $96,852 across 65 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,375,802 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $98 1
2022 General $231 2
2021 General $19,966 8
2020 General $12,300 7
2019 General $64,256 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Dart
  • Medical Toxicology median
  • Middle half of Medical Toxicology
  • National median

In program year 2025, general payments to Richard Dart were reported at $0. Among 30 Medical Toxicology profiles paid that year, the median was $105 and the middle half received between $44 and $290.

Show as a table
Year Richard Dart Medical Toxicology median Middle half National median
2019 $64,256 $110 $28–$420 $163
2020 $12,300 — — $114
2021 $19,966 — — $132
2022 $231 $41 $18–$123 $149
2023 $98 — — $160
2024 $0 $78 $26–$128 $164
2025 $0 $105 $44–$290 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Mallinckrodt LLC $54,480 16 payments
  2. BTG International, Inc. $35,007 14 payments
  3. Rare Disease Therapeutics, Inc. $2,102 8 payments
  4. Purdue Pharma L.P. $1,859 16 payments
  5. Pfizer Inc. $1,352 3 payments
  6. Janssen Research & Development, LLC $1,155 1 payment
  7. Cumberland Pharmaceuticals, Inc. $745 1 payment
  8. Collegium Pharmaceutical, Inc. $114 4 payments
  9. Indivior Inc. $20 1 payment
  10. Janssen Pharmaceuticals, Inc $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $65,530 15 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,445 9 payments
  3. Travel and Lodging $6,319 18 payments
  4. Food and Beverage $1,558 23 payments
Products named General payments · program years 2019–2023
  1. CROFAB Anti-Venom $23,065 7 payments
  2. CROFAB Anti-Venom $11,942 7 payments
  3. ORF $1,720 11 payments
  4. Anavip antivenom $1,589 3 payments
  5. LYRICA $1,352 3 payments
  6. Anavip Antivenin $134 2 payments
  7. XTAMPZA $92 1 payment
  8. Anavip antivenom $69 1 payment
  9. XARELTO $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Toxicology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record